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The association of military blast exposure and brain injury was first appreciated in World War I as commotio cerebri,
and later as shell shock. Similar injuries sustained in modern military conflicts are now classified as mild traumatic
brain injury (TBI). Recent research has yielded new insights into the mechanisms by which blast exposure leads
to acute brain injury and chronic sequelae, including postconcussive syndrome, post-traumatic stress disorder,
post-traumatic headache, and chronic traumatic encephalopathy, a tau protein neurodegenerative disease. Impediments
to delivery of effective medical care for individuals affected by blast-related TBI include: poor insight into the
heterogeneity of neurological insults induced by blast exposure; limited understanding of the mechanisms by
which blast exposure injures the brain and triggers sequelae; failure to appreciate interactive injuries that
affect frontal lobe function, pituitary regulation, and neurovegetative homeostasis; unknown influence of genetic risk
factors, prior trauma, and comorbidities; absence of validated diagnostic criteria and clinical nosology that differentiate
clinical endophenotypes; and lack of empirical evidence to guide medical management and therapeutic intervention.
While clinicopathological analysis can provide evidence of correlative association, experimental use of animal models
remains the primary tool for establishing causal mechanisms of disease. However, the TBI field is confronted by a welter
of animal models with varying clinical relevance, thereby impeding scientific coherence and hindering translational
progress. Animal models of blast TBI will be far more translationally useful if experimental emphasis focuses on accurate
reproduction of clinically relevant endpoints (output) rather than scaled replication of idealized blast shockwaves
(input). The utility of an animal model is dependent on the degree to which the model recapitulates pathophysiological
mechanisms, neuropathological features, and neurological sequelae observed in the corresponding human disorder.
Understanding the purpose of an animal model and the criteria by which experimental results derived from the model
are validated are critical components for useful animal modeling. Animal models that reliably demonstrate clinically
relevant endpoints will expedite development of new treatments, diagnostics, preventive measures, and rehabilitative
strategies for individuals affected by blast TBI and its aftermath.Introduction
Traumatic brain injury (TBI) resulting from blast expos-
ure affects combatants and civilians around the world
[1-3]. Recent estimates indicate that 10 to 20% of the 2.5
million US military service members deployed to Iraq
and Afghanistan may be affected by TBI and the major-
ity of these injuries are associated with blast exposure* Correspondence: lgold@bu.edu
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unless otherwise stated.[4-13]. Individuals exposed to blast are at increased risk of
acute neurological deficits, persistent pathological changes
in the brain, and chronic neuropsychiatric and cognitive
disability [1,10-24]. Blast exposure is a known precipi-
tant of brain injury in animals [22,25-40] and humans
[14,19-22,41-43], including individuals with repeated
exposure to low-level blast [23,24]. Recent research has un-
covered neuropathological and mechanistic connections
between blast exposure and chronic traumatic encephalop-
athy (CTE), a progressive tau protein neurodegenerative
disease documented in athletes with repetitive concussive
and subconcussive head injury [44,45] and in militaryral Ltd. The licensee has exclusive rights to distribute this article, in any medium,
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perimental studies have demonstrated TBI-linked and
CTE-linked tau neuropathology and neurobehavioral defi-
cits in laboratory animals following blast exposure [22,39].
These findings suggest a mechanistically causal connection
between blast exposure and organic brain injury. Collect-
ively, these findings represent a major paradigm shift in
medical understanding of acute and chronic effects of blast
exposure on brain structure and function.
Growing awareness of the long-term consequences of
blast TBI and the large number of returning military ser-
vice members and civilians who have experienced blast ex-
posure necessitate increased research to better understand,
diagnose, and treat acute and chronic effects of blast-
related neurotrauma. Research advances have yielded fun-
damental insights into the neurobiological basis, biomech-
anical determinants, and pathophysiological mechanisms
by which blast exposure induces acute brain injury and
chronic neurological sequelae [22,39]. The field is now
poised for translational research to develop new diagnos-
tics, treatments, preventive measures, and rehabilitative
strategies for individuals affected by blast neurotrauma.
These efforts will be facilitated by critical assessment of
unresolved clinical and translational issues that currently
impede progress on both fronts.
Translational research in this area has been hampered
by a number of methodological issues, including lack of
consensus regarding what constitutes an appropriate ani-
mal model of blast TBI and how to evaluate the validity of
experimental results obtained from these models. To be
useful, animal models must have a well defined purpose
and recapitulate clinically relevant features – including
neuropathological hallmarks, neurophysiological defects,
neurobehavioral deficits, and cognitive impairments – that
correspond to abnormalities observed in humans exposed
to blast. Animal models that accurately recapitulate human
pathology are a critical prerequisite for understanding
pathogenic mechanisms and developing new diagnostics
and therapeutics for TBI and CTE [46]. Determining the
extent to which common neurophysiological mechanisms
eliciting TBI are shared by differing types and severity of in-
cident traumas (for example, blast, impact, polytrauma),
and how these mechanisms contribute to the temporal
course and clinical evolution (for example, persistence, pro-
gression, resolution) of the resulting injuries, will be key
factors for successful translational efforts in this arena. This
review will address key issues for animal models of blast-
related TBI and CTE.
Clinical considerations
Pathobiology of blast traumatic brain injury, chronic
sequelae, and comorbidities
Emerging clinical evidence indicates that repetitive head
injury in contact-sport athletes and blast exposure inmilitary service personnel may be associated with long-
term neuropathology, psychiatric disturbances, endocrine
abnormalities, and cognitive impairment in susceptible in-
dividuals [1-3,15-17,19,22,44,45,47-52]. McKee and col-
leagues recently reported a large case series of postmortem
brains from a cohort of 85 subjects with histories of mild
TBI in which evidence of CTE neuropathology was de-
tected in 68 subjects (mean age, 59.5 years), including 21
military veterans who served in World War II, Korea,
Vietnam, Gulf War, Iraq or Afghanistan [44]. Postmortem
brains from 18 age-matched and sex-matched subjects
without a history of TBI did not demonstrate neuropatho-
logical evidence of CTE. A controlled case series [22] and
a single case report [21] found evidence of CTE neuro-
pathology in postmortem brains from a total of five mili-
tary veterans with documented histories of blast exposure
during deployment to Iraq or Afghanistan, including one
veteran with single blast exposure and no documented
history of antecedent, coincident, or subsequent TBI [22].
Notably, four of the five blast-exposed military veterans
with CTE neuropathology also carried a clinical diagnosis
of post-traumatic stress disorder (PTSD) [22]. A critical
observation from these studies was that CTE pathology
documented in the brains of blast-exposed military vet-
erans was neuropathologically indistinguishable from CTE
pathology observed in the brains of athletes with a history
of repetitive concussive or subconcussive head injury [22].
Neuropathological hallmarks in both groups included
widespread cortical foci of perivascular tau pathology,
microgliosis, astrocytosis, myelinated axonopathy, and
focal neurodegeneration. Clinical symptoms in both groups
were also similar and included progressive affective la-
bility, irritability, distractability, executive dysfunction,
memory disturbances, and cognitive deficits consistent
with CTE [44,45].
A recent study we conducted in a blast neurotrauma
mouse model implicates blast wind-induced acceleration–
deceleration of the head (bobblehead effect) as a pri-
mary pathogenic mechanism by which blast exposure
induces brain injury. Neuropathological hallmarks of
blast neurotrauma in humans and our mouse model in-
clude myelinated axonopathy, focal microvasculopathy,
chronic neuroinflammation, frank neurodegeneration, and
phosphorylated tau proteinopathy [22]. Critically import-
ant in this study are experimental findings obtained from
a blast neurotrauma mouse model that recapitulated core
neuropathological and neurobehavioral features of blast-
related TBI and CTE in humans. The results of this study
identified common pathogenic determinants leading to
CTE in blast-exposed military veterans and head-injured
athletes [22]. This same study provided mechanistic evi-
dence that supports this association by showing that la-
boratory mice exposed to experimental blast also develop
TBI-linked and CTE-linked neuropathology [22,39].
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related sequelae suggest common pathobiology, the neuro-
biological substrates and pathophysiological mechanisms
underpinning these clinical entities and interactions are
poorly understood. Moreover, the temporal course of sec-
ondary responses in the peri-acute and chronic stages
following acute injury is largely unknown. Recently, a
number of blue ribbon committees have reviewed the
available clinical evidence and established consensus defi-
nitions with respect to diagnostic criteria and management
guidelines for TBI, concussion, and related conditions
[53-58]. While these efforts have brought some order to
the field, the reality is that diagnosis, prognosis, triage, and
monitoring for these conditions remain grounded on clin-
ical criteria with unproven relationships to underlying
pathophysiology. As a consequence, clinical nosology and
pathophysiological understanding are uncoupled. This
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intervention for TBI and related sequelae. What little is
known of TBI pathobiology suggests that optimal clinical
care requires consideration of interacting pathologies that
affect different brain regions and lead to different symp-
toms (Figure 1).
Recent evidence linking blast exposure to development
of CTE [21,22,44] underscores the importance of consid-
ering the highly heterogeneous nature of the inciting
traumatic injuries and the complex pathobiological in-
teractions that arise in the setting of mild TBI [59]. CTE
is a slowly progressive tau protein-linked neurodegener-
ative disease associated with sports-related concussive
and subconcussive head injury as well as military-related
blast exposure [21,22,44]. While phosphorylated tau pro-
tein neuropathology is a prominent component of CTE,
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nlikely to be effective.
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lopathy, perivascular neuroinflammation, and myelinated
axonopathy; a distinctive pathological distribution pattern
(for example, predilection for sulcal depths, focal perivas-
cular epicenters) that implicates biomechanical injury at
sites of shear stress concentration; involvement of other
CTE-associated pathogenic proteins (for example, TAR
DNA-binding protein 43); and a characteristic pathological
progression that correlates with clinical symptoms [44].
Converging evidence suggests that tau proteinopathies
may involve prion-like propagation in the brain [60-62];
however, this mechanism remains speculative with respect
to disease progression in CTE.
The clinical presentation in CTE includes attentional
and concentration disturbances, short-term memory prob-
lems, impulsivity, irritability, chronic headache, explosive
aggression, sleep and mood disturbances, psychosocial im-
pairments, and suicidality [44,45,63]. Clinical features of
CTE overlap significantly with PTSD [64,65], a profoundly
disabling neuropsychiatric disorder that is often associated
with blast TBI.
The clinical courses of TBI, CTE, and, to some extent,
PTSD are variable, frequently overlap clinically, and
often include neuropsychiatric signs and symptoms at-
tributable to organic brain syndromes that affect the
frontal lobes. Since the frontal lobes are anatomically
vulnerable to traumatic injury, it is not surprising that
TBI-related neuropathology often involves this brain re-
gion. Characteristic disturbances of frontal lobe function
include impairments in working memory, planning, multi-
tasking, complex decision-making, judgment, empathy, and
executive function [66,67]. Changes in personality and so-
cial behavior may be prominent. Other notable signs of
frontal lobe dysfunction are impulsivity, emotional lability,
and disinhibition. Global damage to frontal lobe function is
characteristically marked by an inability to inhibit stimulus-
initiated behavioral programs [66,67]. Neurological de-
rangements involving the frontal lobes can thus result in
release of inappropriate, impulsive, or maladaptive behav-
iors that would otherwise be inhibited. Persistent frontal
lobe dysfunction following blast TBI may result in failure
to extinguish responses to trauma-related stimuli and
maintenance of stimulus–response linkages. Blast-related
TBI is commonly associated with PTSD, and in this set-
ting frontal lobe dysfunction may result in symptom per-
sistence, resistance to cognitive behavioral interventions,
and increased risk of maladaptive, impulsive, and injurious
behaviors. In the military context, frontal lobe-mediated
neuropsychiatric disturbances may compromise oper-
ational judgment, tactical performance, personnel safety,
and mission objectives.
Individuals affected by blast TBI present many chal-
lenges with respect to clinical management, longitudinal
monitoring, and risk assessment. In addition, therapeuticresponses in this population may be highly variable as a
consequence of the heterogeneous nature of the inciting
traumas, affected neuroanatomical substrates, and under-
lying pathobiological responses. Patients with confirmed
or suspected organic brain syndromes involving the
frontal lobes present additional challenges. For these rea-
sons, a one-size-fits-all management approach for blast
TBI is unlikely to be effective. These considerations also
underscore the importance of pathobiologically informed
diagnostic classifications, subtype identification based on
affected neurobiological systems, and differential diagno-
ses that include common comorbidities (for example, sub-
stance use disorders, major affective disorders, PTSD).
The need for longitudinal care and clinical vigilance in this
setting is paramount.
Pathobiologically informed diagnostic criteria and
biomarkers
Microscopic structural changes in the brain that characterize
blast TBI and related sequelae cannot be identified during
life using currently available diagnostic tools. A number
of candidate biomarkers of mild TBI have been iden-
tified in blood and cerebrospinal fluid, including S100-B,
myelin basic protein, neuron-specific enolase, glial fibril-
lary acidic protein, ubiquitin carboxy-terminal hydrolase
L1, spectrin breakdown products, microtubule-associated
tau protein, secreted forms of the amyloid precursor
protein (sAPP-α, sAPP-β), γ-enolase, neurofilament poly-
peptide species, various interleukins and cytokines, and
small noncoding RNA molecules (reviewed in [3,68-75]).
A variety of neuroimaging markers have been identi-
fied and proposed as diagnostic biomarkers of mild
TBI [48,76,77].
Despite these advances, the pathobiology of blast-related
TBI remains poorly understood, thus impeding clinical
validation of TBI-specific biomarkers and risk factors.
These gaps compromise diagnostic evaluation, endophe-
notype differentiation, clinicopathological correlation, and
epidemiological characterization. In addition, the absence
of validated biomarkers for mild TBI undermines screen-
ing, prognosis, staging, risk assessment, and longitudinal
monitoring. Moreover, different biomarkers may be
needed to detect and differentiate TBI persistence, pro-
gression, and conversion to chronic sequelae, including
CTE. The urgent need for diagnostic biomarkers extends
to commonly associated comorbidities such as PTSD.
Validated biomarkers are also needed for clinical trial
evaluation of emerging therapeutics. Cohort stratification,
therapeutic efficacy, and regulatory clearance critically
depend on clinical biomarker sensitivity, specificity, and
utility. Indeed, biomarker availability poses a ‘go–no go’
challenge for development of effective treatments. In this
regard, the logic and strategy for biomarker assessment in
Alzheimer’s disease is instructive [78].
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Genetic factors, epigenetic changes, environmental expo-
sures, trauma history, interaction with comorbid condi-
tions, and other modulatory factors (for example, age, sex,
medical history, environmental exposures, lifestyle and
nutritional factors) collectively comprise an individual’s
risk profile for disease expression and progression. Identi-
fication of major risk and modulatory factors is essential
for understanding disease risk, initiation, progression, and
outcome. Genetic markers of increased vulnerability to
neurotrauma are emerging and numerous studies impli-
cate apolipoprotein E4 as a major genetic risk factor asso-
ciated with poor clinical outcome after TBI (reviewed in
[79-83]). Analysis of other genetic risk factors, epigenetic
markers, and other modulatory influences will require vali-
dated clinical and molecular phenotyping based on disease-
linked attributes and mechanistic interpretation based on
detailed understanding of the underlying pathobiology.
Need for effective treatments and preventive measures
Optimal clinical care for individuals affected by blast
TBI and related conditions is dependent on availability
of safe and effective therapy. Unfortunately, there are no
currently available US Food and Drug Administration-
approved treatments to halt, slow, reverse, or correct the
underlying pathobiology. Direct and indirect costs associ-
ated with this therapy gap for military-related TBI, seque-
lae, and comorbidities, although unknown, are undoubtedly
large and likely to increase over time given the types of
injuries and numbers of affected service members andFigure 2 Translational research pathways and relationship to basic and
of safe and effective diagnostics and therapeutics for blast traumatic brain
detailed mechanistic understanding of the underlying pathology (clinical sc
the disease (initiation, progression, interaction, termination). A strong clinic
identification and validation of new diagnostic biomarkers and therapeutic
these efforts. Collaborative partnerships with biotechnology and pharmace
risk, and – under favorable conditions – shoulder transition costs, including p
safety and toxicological testing, preclinical efficacy evaluation, and clinical triaveterans [84,85]. A major factor contributing to the
absence of effective treatments for TBI-related conditions
is attributable to the limited knowledge and heteroge-
neous nature of pathogenic mechanisms underpinning
TBI-related injuries, secondary responses, chronic sequelae,
and associated comorbidities. Rational therapeutic develop-
ment and efficient clinical delivery of effective therapeutic
and prophylactic interventions for TBI will be greatly facili-
tated by robust multidisciplinary translational research fo-
cused on identifying pathogenic mechanisms, therapeutic
targets, diagnostic biomarkers, and pathobiology-modifying
interventions (Figure 2).
As for many multifactorial disorders with complex eti-
ologies, a clinical armamentarium for TBI is expected to
include a variety of small-molecule pharmaceuticals that
target distinct pathways altered by TBI as well as ad-
junctive treatments, including nutraceuticals, electroceu-
ticals, cognitive behavioral therapies, computer-assisted
technologies, and other therapeutic modalities. Our recent
observations that blast exposure can produce persistent
impairments in synaptic plasticity essential for learning
and memory [21] support the idea that bioavailable small-
molecule therapeutics that modulate neurotransmission
and synaptic plasticity should be considered high-priority
targets for TBI-related conditions. Similarly, the potential
for some overlap in neuropathology associated with TBI
and neurodegenerative diseases further supports the idea
of developing adjunctive therapeutics with synergistic cog-
nitive enhancing effects. Regardless of the targets, one
point is clear: development of effective interventions forclinical sciences. Rational development and clinical implementation
injury, related sequelae, and associated comorbidities will require
ience) and pathogenic mechanisms (basic science) across all stages of
al and basic science foundation is an essential prerequisite for efficient
targets. Multidisciplinary translational research teams are essential for
utical companies can provide additional resources, share development
roduct development, intellectual property and regulatory management,
l testing.
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without further progress in understanding the substrate
pathobiology.
Translational considerations
Multidisciplinary translational research is essential for
clinical progress
Clinical delivery of effective diagnostics, therapeutics, pre-
ventive measures, and rehabilitative strategies for TBI-
related indications will require substantial investment to
support multidisciplinary translational research teams with
expertise, technical resources, and infrastructure that span
various clinical specialties (for example, neurology, neuro-
surgery, psychiatry, pathology), basic and applied sciences
(for example, neurobiology, genetics, physiology, pharma-
cology, psychology, medicinal chemistry), and engineering
disciplines (for example, mechanical, biomedical, bioinfor-
matics). A new cadre of investigators and multidisciplinary
collaborations is needed to advance translational progress,
stimulate transformative innovation, and accelerate devel-
opment of safe and effective clinical products for TBI and
related conditions. A well-resourced national initiative is
urgently needed to attract, motivate, support, and sustain
the nation’s best and brightest to enter the field, evaluate
high-risk/high-reward hypotheses, and translate scientific
advances into clinically useful diagnostics, therapeu-
tics, preventive measures, and rehabilitative strategies.
A successful translational strategy will probably in-
clude bio-innovators with proven track records of or-
ganizing translationally oriented research teams that
successfully tackle challenging biomedical problems with
innovative solutions. Paradigm-shifting advances are likely
to be made by research teams that are capable of working
across boundaries between established disciplines and
willing to consider outsider perspectives [86]. An environ-
ment that fosters truly transformative innovation will
require focus on long-term objectives, incentives for risk-
taking, tolerance for failure, and merit-based evaluation
that prioritizes disjunctive innovation and translational
success over incremental progress.
Translational considerations for blast traumatic brain
injury animal modeling
Elucidating pathobiological mechanisms and identifica-
tion of therapeutic targets based on pathophysiological
understanding are sine qua non for translational devel-
opment of new clinical armamentarium for TBI-related
indications. Many fundamental issues related to blast
neurotrauma are just beginning to be explored, in-
cluding blast effects on neuronal function and physiology,
microvascular structure and function, blood–brain barrier
integrity, neuroinflammation and secondary responses,
and brain network dynamics. Recently recognized con-
nections between blast neurotrauma and persistentfunctional axonopathy and brain proteinopathy involv-
ing the microtubule-associated tau protein have only re-
cently been recognized and require intensive investigation
[22,39]. The biological underpinnings of variabilities in
clinical presentation, temporal course, long-term outcome,
and individual susceptibility are poorly understood. Prog-
nostic assessment in this setting is largely a matter of
guesswork. The current situation reflects large knowledge
gaps in understanding the pathobiology of acute blast neu-
rotrauma and its aftermath. These knowledge gaps can be
addressed by translational research that utilizes animal
models of blast neurotrauma.
Animal models are essential tools in the translational
research armamentarium. Experimental use of animal
models enables hypothesis testing under controlled con-
ditions that are often not possible in clinical research. In
fact, many clinically relevant neurophysiological parame-
ters can only be assessed in the context of animal exper-
iments. The benefits of human TBI research in terms of
relevance is often counterbalanced by technical limita-
tions, ethical challenges, and study confounds, including
limited cohort size and inclusion of subjects with hetero-
geneous injuries and multiple etiologies, diverse trauma
histories, complicating comorbidities, and diverse risk fac-
tor profiles [59]. Moreover, clinicopathological correlation
analysis, a core component of experimental studies involv-
ing animals, is often difficult or impossible in human sub-
ject research. For these reasons, translational research
utilizing animal models is an essential requirement for ad-
vancing medical understanding and clinical progress.
Fundamental to animal modeling is the definition of pur-
pose [87,88]. Much debate in the field has centered on
standardizing animal models and experimental protocols.
In fact, a strong argument can be made that standardization
will constrain rather than facilitate translational progress.
Rather than standardization, what is needed is clarity re-
garding the purpose of particular models and protocols
(‘what is the model modeling?’) and the validity of results
and interpretations that flow from particular animal models
and experimental protocols (’what do the experimental re-
sults mean?’). The number of different animal models is
irrelevant. However, the interpretation and validity of ex-
perimental results derived from particular animal models
are matters of great significance.
Animal models are developed and deployed for a var-
iety of purposes, including: identification of biological
substrates and pathogenic mechanisms; elucidation and
validation of therapeutic targets and diagnostic markers;
assessment of risks associated with new interventions; and
translation of preclinical insights into clinical practice.
The purpose of any particular animal model is important
in so far as this purpose, declared or implied, constrains
the generality and explanatory power of the answers pro-
vided by the model [87,88]. Moreover, the interpretability
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major criterion by which experimental and interpretive
validity is established. Important in this context is the fact
that validation is not conferred on an animal model per se,
but rather on the quality and interpretation of experimen-
tal data arising from a model and on the experimental
concordance of the model with clinical features and
pathobiology of the human disorder that is being modeled
[87-90]. The designation of a validated animal model thus
has no inherent meaning independent of the context in
which the animal model and derivative experimental re-
sults are evaluated.
These concepts are important to consider in the context
of animal modeling relevant to TBI research. For example,
an animal model of blast neurotrauma that emphasizes
precise scaling of Friedlander blast characteristics but does
not replicate brain pathology and neurobehavioral deficits
corresponding to neuropathological and clinical features
observed in blast-exposed humans may prove to be an
ideal experimental system for ballistics investigations, but
provides only limited information of clinical relevance
with respect to blast TBI in humans. Conversely, an ani-
mal model of blast neurotrauma that reliably recapitulates
neuropathology and neurobehavioral deficits observed in
blast-exposed humans may prove useful in providing
clinically relevant information regarding blast TBI, but
less informative with respect to accurate determination of
scaling factors and biomechanical constants for finite
element analysis. A caveat is required in experimental cir-
cumstances in which deployment of a pathobiologically
informed animal model provides superior mechanistic
insights (that is, construct validity) and explanatory
generalizability (that is, external validity), such that deriva-
tive biomechanical analyses are actually more rather than
less clinically relevant. This is the case in recent studies
that have combined military-relevant blast exposure con-
ditions with animal models that exhibit clinically relevant
acute and chronic blast-related neuropathology and func-
tional sequelae [22,39].
These considerations also apply to evaluating the val-
idity of experimental results that use animal models. For
example, the validity and relevance of experimental stud-
ies that use blast TBI animal models are frequently chal-
lenged on the basis of interspecies scaling factors and
other methodological technicalities. Such arguments rep-
resent category errors, and as such are logically flawed.
While technical concerns may warrant debate, these cri-
teria are inappropriate for evaluation of experimental
validity. As noted above, validation is not conferred or
rejected based on the animal model per se, but rather on
the quality and interpretation of experimental data derived
from a particular animal model and applicability to mech-
anistic underpinnings of human TBI. Simply stated, the
validity of experiments using any animal model stands orfalls on the cumulative merits of the scientific results eval-
uated according to established criteria. By convention, val-
idation criteria include: internal validity (reproducibility,
replication); face validity (correspondence to clinicopatho-
logical features in humans); construct validity (fitness to
known or suspected pathobiology); and, most importantly,
predictive value and generalizability (empirical extrapola-
tion and validation under different conditions, and ideally
across species) [87-90]. Interspecies scaling factors and
other methodological matters may be important for bio-
mechanical calculations, but do not figure in assessing the
validity of animal experiments designed to investigate the
pathobiology of blast-related neurotrauma and chronic
neurological sequelae.
Reframing experimental focus on brain rather than blast
Evaluation of experimental results obtained from studies
that utilize animal models of blast TBI are obligated to
consider the degree to which model concordance reflects
blast-related abnormalities in humans. Clinical relevance
and translational utility demand that animal models of
blast neurotrauma emphasize experimental fidelity of
the resulting brain injury in the context of the inciting
traumatic insult. Insistence on animal models that re-
quire accurately scaled versions of military-relevant blast
is fundamentally misguided if these models are not ac-
companied by evidence of neuropathology and neurobe-
havioral deficits that reflect corresponding abnormalities in
blast-exposed humans. In this context, structure–function
isomorphy represents a core principle for animal model
comparison and experimental generalizability. Focus on
blast (input) at the expense of brain (output) is unlikely to
yield clinically relevant translational benefits of significance
to blast TBI and sequelae in humans.
A number of additional translational issues merit consid-
eration for TBI animal modeling. These include the nature
of blast production and exposure, internal versus external
placement and orientation of the animal subject relative to
the blast tube, presence or absence of cervical and head
immobilization [22,39], use of thoracic protection, moni-
toring for blast-induced barotrauma and post-exposure
apnea, anesthetic and analgesic effects with respect to cer-
vical muscle tone and cerebral oxygenation, and consider-
ation of ultrafast (for example, microsecond) timescales for
biomechanical analyses. The need for multimodal analyses,
biological–pathological correlation, and human clinico-
pathological validation is of paramount importance. How
these and other TBI animal modeling issues are addressed
within a specific experimental context will depend on the
questions under investigation. Regardless, interpretation of
the resulting experimental data is subject to the same val-
idation criteria discussed above. Critical appraisal and ex-
pert consensus regarding these translational issues will go
a long way towards fostering progress in the field.
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Although investigation of blast-related TBI is proceeding
at an unprecedented pace, a number of unresolved issues
hinder research and clinical progress. Impediments to ef-
fective clinical care include limited understanding of the
detailed mechanisms and specific circumstances by which
blast exposure leads to acute brain injury and chronic
neurological sequelae, poor insight into how blast-related
TBI may impact different brain structures leading to vari-
able functional deficits (for example, frontal lobe and dis-
connection syndromes, chronic pain and major affective
disorders, hypopituitarism and endocrinological distur-
bances), unknown influence of genetic risks and modula-
tory factors (for example, age, sex, medical history, prior
trauma, comorbidities), and absence of validated diagnostic
criteria, disease-linked biomarkers, and disease-modifying
treatments that reflect understanding of the substrate
pathobiology. Implementation of robust multidisciplinary
research programs that utilize relevant blast TBI animal
models validated by correspondence to human neuropath-
ology and functional deficits will advance understanding of
pathogenic mechanisms, accelerate translational progress,
and benefit medical care for individuals affected by acute
and chronic effects of blast-related neurotrauma.
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